05:12 PM EDT, 07/15/2025 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) said Tuesday the UK's Medicines and Healthcare products Regulatory Agency approved Ekterly, its oral treatment for hereditary angioedema attacks.

Ekterly, containing sebetralstat, is cleared for patients aged 12 and older.

The approval is based on the phase 3 trial, which showed faster symptom relief, reduced attack severity, and higher resolution rates than placebo, with a comparable safety profile.

Ekterly also qualifies for orphan drug status in the UK, providing up to 10 years of market exclusivity, according to the company.

Shares of KalVista were up nearly 1% in after-hours trading.